Your trusted source for the latest news and press releases
www.ir-world.com | office@ir-world.com | +43 7242 211930-11

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

Share this Article

Press release distributed by IRW-Press.com. The issuer is responsible for the content.
Free reprinting permitted with source attribution.

BioNxt Solutions Inc.

ISIN: CA0909741062

more news from this Company

SIGN UP FOR COMPANY NEWS

Subscription to Company

Name

Email Address

Company

I have read and agree to the Terms and Conditions and Privacy Policy